TLR4 and metabolic dysfunction-associated steatotic liver disease: The TLR4 signaling, whose role in inflammation and fibrosis has extensively been described above, represents another promising target for the treatment of NAFLD: in particular JKB-121, a weak TLR4 receptor antagonist, has been studied in a phase II trial [175].